Role of alpha interferon in multiple myeloma (Q41711760)

7 October 2017

1 reference

title

Role of alpha interferon in multiple myeloma (English)

1 reference

7 October 2017

Joshua DE

1

1 reference

7 October 2017

MacCallum S

series ordinal

2

1 reference

7 October 2017

Gibson J

series ordinal

3

1 reference

7 October 2017

publication date

1 December 1997

1 reference

7 October 2017

1 reference

7 October 2017

volume

11

1 reference

7 October 2017

issue

4

1 reference

7 October 2017

page(s)

191-200

1 reference

Interferon therapy in myelomatosis

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Effects of cloned human leukocyte interferons in the human tumor stem cell assay

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Role of interferon-induced enzymes in the antiviral and antimitogenic effects of interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Development of transformed phenotype induced by a human ras oncogene is inhibited by interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Antibodies to human leucocyte interferons in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

The role of the bcl-2 gene in lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl‐2 oncoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Allogeneic bone marrow transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

Alpha-interferon combination therapy of resistant myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990019-9

7 January 2021

10.1016/S0268-960X(97)90019-9

Identifiers

DOI

1 reference

7 October 2017

1 reference